Literature DB >> 8417818

Neopterin and prognosis in patients with adenocarcinoma of the colon.

G Weiss1, P Kronberger, F Conrad, E Bodner, H Wachter, G Reibnegger.   

Abstract

Concentrations of neopterin, a sensitive indicator for the activation of cellular immunity, were measured in urine samples of 44 patients with adenocarcinoma of the colon at diagnosis. To judge the relative predictive value of neopterin concentrations, other routine clinical and laboratory variables were concomitantly determined. The patients were then followed up to 10 yr, and the abilities of all variables to predict death from cancer were assessed. Neopterin concentrations were not correlated with either tumor stage or Dukes' stage. In univariate analyses using the product-limit approach, four variables were significant indicators of poor prognosis: presence of distant metastases (P = 0.0001); high Dukes' stage (P = 0.0009); high urinary neopterin concentration (P = 0.0034); and advanced stage (P = 0.030). Presence versus absence of lymph node metastases was not associated with prognosis. Multivariate survival analyses by the proportional hazards technique demonstrated that neopterin provided statistically independent predictive information in addition to either presence versus absence of distant metastases or Dukes' stage. When neopterin and tumor stage were investigated for joint prediction, stage failed to be included in the model. Thus, neopterin concentrations provide valuable and statistically independent prognostic information in patients with adenocarcinoma of the colon.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417818

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma.

Authors:  H Tilg; C van Montfrans; A van den Ende; A Kaser; S J H van Deventer; S Schreiber; M Gregor; O Ludwiczek; P Rutgeerts; C Gasche; J C Koningsberger; L Abreu; I Kuhn; M Cohard; A LeBeaut; P Grint; G Weiss
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 2.  Neopterin as a biomarker of immune response in cancer patients.

Authors:  Bohuslav Melichar; Martina Spisarová; Marie Bartoušková; Lenka Kujovská Krčmová; Lenka Javorská; Hana Študentová
Journal:  Ann Transl Med       Date:  2017-07

3.  Roles of tetrahydrobiopterin in promoting tumor angiogenesis.

Authors:  Liye Chen; Xin Zeng; Jihui Wang; Simon S Briggs; Eric O'Neill; Jiliang Li; Russell Leek; David J Kerr; Adrian L Harris; Shijie Cai
Journal:  Am J Pathol       Date:  2010-09-16       Impact factor: 4.307

4.  Diminished quality of life in patients with cancer correlates with tryptophan degradation.

Authors:  Katharina Schroecksnadel; Michael Fiegl; Karin Prassl; Christiana Winkler; Hubert A Denz; Dietmar Fuchs
Journal:  J Cancer Res Clin Oncol       Date:  2007-03-14       Impact factor: 4.553

5.  Simultaneous determination of xanthopterin and isoxanthopterin in human urine by synchronous fluorescence spectroscopy.

Authors:  Yi-Qun Wan; Li-Juan Tang; Ting Tan
Journal:  J Fluoresc       Date:  2010-04-24       Impact factor: 2.217

6.  Urinary neopterin levels in patients with thyroid cancer.

Authors:  Serap Soytac Inancli; Sedat Caner; Fevzi Balkan; Abbas Ali Tam; Gulnur Guler; Reyhan Ersoy; Bekir Cakir
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-02-18

Review 7.  Anaemia of cancer: an overview of mechanisms involved in its pathogenesis.

Authors:  H Z W Grotto
Journal:  Med Oncol       Date:  2007-09-02       Impact factor: 3.064

8.  Serum neopterin levels in patients with breast cancer.

Authors:  Yesim Yildirim; Nazan Gunel; Ugur Coskun; Hatice Pasaoglu; Sabahattin Aslan; Abdullah Cetin
Journal:  Med Oncol       Date:  2008-03-05       Impact factor: 3.064

9.  A prospective study of the immune system activation biomarker neopterin and colorectal cancer risk.

Authors:  Krasimira Aleksandrova; Shu-Chun Chuang; Heiner Boeing; Hui Zuo; Grethe S Tell; Tobias Pischon; Mazda Jenab; Bas Bueno-de-Mesquita; Stein Emil Vollset; Øivind Midttun; Per Magne Ueland; Veronika Fedirko; Mattias Johansson; Elisabete Weiderpass; Gianluca Severi; Antoine Racine; Marie-Christine Boutron-Ruault; Rudolf Kaaks; Tilman Kühn; Anne Tjønneland; Kim Overvad; J Ramón Quirós; Paula Jakszyn; María-José Sánchez; Miren Dorronsoro; Maria-Dolores Chirlaque; Eva Ardanaz; Kay-Tee Khaw; Nicholas J Wareham; Ruth C Travis; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Domenico Palli; Sabina Sieri; Rosario Tumino; Salvatore Panico; Anne M May; Richard Palmqvist; Ingrid Ljuslinder; So Yeon J Kong; Heinz Freisling; Marc J Gunter; Yunxia Lu; Amanda J Cross; Elio Riboli; Paolo Vineis
Journal:  J Natl Cancer Inst       Date:  2015-02-23       Impact factor: 13.506

10.  The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.

Authors:  Yuan Wang; Guo-Fang Hu; Zhe-Hai Wang
Journal:  Onco Targets Ther       Date:  2017-07-19       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.